Literature DB >> 9290443

Management of low-grade squamous intraepithelial lesions during pregnancy.

A G Jain1, R V Higgins, M J Boyle.   

Abstract

OBJECTIVE: Our purpose was to determine whether prenatal colposcopy is beneficial in pregnant women with squamous atypia, atypical squamous cells of undetermined significance, or low-grade squamous intraepithelial lesions on an initial screening Papanicolaou smear. STUDY
DESIGN: A retrospective chart review identified a cohort of pregnant patients referred to the colposcopy clinic at Carolinas Medical Center between October 1991 and December 1994 with squamous atypia, atypical squamous cells of undetermined significance, or low-grade squamous intraepithelial lesions. Results of the colposcopic examination, cervical biopsy specimens, postpartum evaluation, and postpartum treatment were recorded. Descriptive statistics were used to tabulate numbers and percentages for all variables with 95% confidence intervals to determine disease progression.
RESULTS: Prenatal colposcopy was performed on 253 women during the study period. The colposcopic impression was normal or consistent with low-grade squamous intraepithelial lesions in 235 (93%) of the women. Of the 67 women who had a cervical biopsy, 6 had a histologic diagnosis of high-grade squamous intraepithelial lesions. Postpartum Papanicolaou smears were obtained in 224 patients; 71 (32%) were normal, 145 (65%) were unchanged, and 8 (3%) showed high-grade squamous intraepithelial lesions. Of the 69 patients who had a postpartum cervical biopsy, 4 were found to have high-grade squamous intraepithelial lesions. Eight of the 10 women with biopsy-proved high-grade squamous intraepithelial lesions were compliant with treatment after delivery. Histologic examination of the cervix with tissue obtained by either loop conization or cold knife conization showed no evidence of invasive carcinoma.
CONCLUSION: Squamous atypia, atypical squamous, cells of undetermined significance, or low-grade squamous intraepithelial lesions on a Papanicolaou smear in a pregnant patient does not require colposcopic evaluation during pregnancy. Progression of low-grade dysplasia to carcinoma during pregnancy is unusual, and no patient in this study was found to have invasive cancer.

Entities:  

Mesh:

Year:  1997        PMID: 9290443     DOI: 10.1016/s0002-9378(97)70190-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Atypical Papanicolaou smear in pregnancy.

Authors:  Thomas P Connolly; A C Evans
Journal:  Clin Med Res       Date:  2005-02

2.  Cervical cancer in pregnant women: treat, wait or interrupt? Assessment of current clinical guidelines, innovations and controversies.

Authors:  Sileny N Han; Mina Mhallem Gziri; Kristel Van Calsteren; Frédéric Amant
Journal:  Ther Adv Med Oncol       Date:  2013-07       Impact factor: 8.168

3.  Course of cervical intraepithelial neoplasia diagnosed during pregnancy.

Authors:  Donata Grimm; Isabelle Lang; Katharina Prieske; Anna Jaeger; Volkmar Müller; Sascha Kuerti; Eike Burandt; Susanne Lezius; Barbara Schmalfeldt; Linn Woelber
Journal:  Arch Gynecol Obstet       Date:  2020-04-22       Impact factor: 2.344

Review 4.  Natural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literature.

Authors:  Mariella Mailath-Pokorny; Richard Schwameis; Christoph Grimm; Alexander Reinthaller; Stephan Polterauer
Journal:  BMC Pregnancy Childbirth       Date:  2016-04-07       Impact factor: 3.007

5.  High-risk human papillomavirus clearance in pregnant women: trends for lower clearance during pregnancy with a catch-up postpartum.

Authors:  M A E Nobbenhuis; T J M Helmerhorst; A J C van den Brule; L Rozendaal; P D Bezemer; F J Voorhorst; C J L M Meijer
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640

Review 6.  Diagnosis and treatment of cervical cancer in pregnant women.

Authors:  Nitish Beharee; Zhujun Shi; Dongchen Wu; Jinhua Wang
Journal:  Cancer Med       Date:  2019-08-06       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.